Thermo Fisher Scientific INSM1 Recombinant Rabbit Monoclonal Antibody (ZR283), RAbMono

Applications

Tested Dilution

Publications

Immunohistochemistry (Paraffin) (IHC (P))

Ready-to-use 150-200 µL

-

Product Specifications

Host/Isotype

Rabbit / IgG

Class

Recombinant Monoclonal

Type

Antibody

Clone

ZR283

Immunogen

Full-length human INSM1 protein if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:INSM1,uniProtId:Q01101-1,ncbiNodeId:9606,antigenRange:1-510,antigenLength:510,antigenImageFileName:Z2598RP_INSM1_Q01101-1_Rabbit.svg,antigenImageFileNamePDP:Z2598RP_INSM1_Q01101-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Storage conditions

2-8°C

Shipping conditions

Wet ice

Product Specific Information

This product is diluted and in a ready-to-use formulation.

A recommended positive control tissue for this product is Pancreas, however positive controls are not limited to this tissue type.

The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.

Insulinoma-associated 1 (INSM1) gene is intronless and encodes a protein containing both a zinc finger DNA-binding domain and a putative prohormone domain. It localizes to the nucleus and is expressed in embryonic issues undergoing neuroendocrine differentiation. This gene is a sensitive marker for neuroendocrine tumors of various origins, including lung, GI, and pancreas. INSM1 is sensitive and specific to be a single first-line pan-neuroendocrine marker.

Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.

Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

Target Information

IA-1, also known as INSM1, is an essential five zinc-finger transcription factor that while initially identified from an insulinoma cDNA library, is expressed in the developing nervous system. Specifically, IA-1 is expressed as early as E9.5 in mice in the fore-, mid- and hindbrain, spinal cord, retina, and olfactory bulb. It is thought that IA-1 functions as a transcriptional repressor, and is a part of several signaling pathways including those of Notch and sonic hedgehog in addition to that of Ngn3 during pancreatic endocrine cell differentiation. IA-1 is also expressed in multiple tumors, including the majority of neuroendocrine tumors tested so far as well as nearly 100% of all small cell lung carcinomas, indicating that IA-1 may be an important target in cancer therapy.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.